bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Video 2 from Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells
Authors: Ganguly Anutosh , Yang Hailing , Zhang Hong , Cabral Fernando , Patel Kamala D.
Published: April 2023

MOV file - 3602K, Migration of HUVEC in the presence of 1 nM paclitaxel.
Supplementary Video 1 from Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells
Authors: Ganguly Anutosh , Yang Hailing , Zhang Hong , Cabral Fernando , Patel Kamala D.
Published: April 2023

MOV file - 3617K, Migration of HUVEC.
Supplementary Tables 1 - 4 from Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells
Authors: Ganguly Anutosh , Yang Hailing , Zhang Hong , Cabral Fernando , Patel Kamala D.
Published: April 2023

PDF file - 78K, Table S1. Microtubule dynamics in HUVEC in the presence and absence of paclitaxel. Table S2. Microtubule dynamics in HUVEC in the presence and absence of vinblastine. Table S3. Microtubule dynamics in HUVEC in the presence and absence of colchicine. Table S4. Microtubule dynamics in the leading and trailing edges of HUVEC.
Supplementary Figure Legend from Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells
Authors: Ganguly Anutosh , Yang Hailing , Zhang Hong , Cabral Fernando , Patel Kamala D.
Published: April 2023

PDF file - 56K
Supplementary Figure 6 from Redirecting Apoptosis to Aponecrosis Induces Selective Cytotoxicity to Pancreatic Cancer Cells through Increased ROS, Decline in ATP Levels, and VDAC
Authors: Dinnen Richard D. , Mao Yuehua , Qiu Wanglong , Cassai Nicholas , Slavkovich Vesna N. , Nichols Gwen , Su Gloria H. , Brandt-Rauf Paul , Fine Robert L.
Published: April 2023

PDF - 345KB, Supplementary Figure S6: A, ROS accumulation (MitoSOX Red) and cell death (Trypan blue) in AAA-treated PANC-1 cells treated with increasing concentrations of MnTMPyP, (10 muM MnTMPyP). B, ROS accumulation and cell death (Trypan blue) in AAA-PANC-1 cells treated with KCN (5 mM). Relative increase in percentage of ROS (O2.- radical) is shown in inset. C, AAA-treated PANC-1 cells, treated with 300 muM DIDS for 6h as measured by flow cytometry using MitoSOX Red. Relative increase in percentage of ROS (O2.- radical) is shown in inset.
Supplementary Table 1 from Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma
Authors: Mirzoeva Olga K. , Collisson Eric A. , Schaefer Peter M. , Hann Byron , Hom Yun K. , Ko Andrew H. , Korn W. Michael
Published: April 2023

PDF - 1610K, List of Predictors.
Supplementary Figure 4 from Redirecting Apoptosis to Aponecrosis Induces Selective Cytotoxicity to Pancreatic Cancer Cells through Increased ROS, Decline in ATP Levels, and VDAC
Authors: Dinnen Richard D. , Mao Yuehua , Qiu Wanglong , Cassai Nicholas , Slavkovich Vesna N. , Nichols Gwen , Su Gloria H. , Brandt-Rauf Paul , Fine Robert L.
Published: April 2023

PDF - 1216KB, Supplementary Figure 4: A, Flow cytometric analysis for blue autofluorescence indicating cells with higher or lower levels of reduced NADH. B, Mitochondrial membrane potential of the same cells shown in part A. A mitochondrial membrane potential decrease in the red/green (FL-2/FL-1) fluorescence intensity of JC-1 probe. Colors correspond to cells shown in A. For determination of NADH levels, a Becton Dickinson LSR Flow Cytometer equipped with a 325nm Helium-Cadmium UV laser was used.
Supplementary Figure 3 from Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma
Authors: Mirzoeva Olga K. , Collisson Eric A. , Schaefer Peter M. , Hann Byron , Hom Yun K. , Ko Andrew H. , Korn W. Michael
Published: April 2023

PDF - 968K, Western blot analysis of the biochemical response of two epithelial (HPAF-II and Panc10.05) and two mesenchymal (Panc2.13 and PA-TU8988T) PDAC cell lines treated with MEK inhibitor CI1040 in the presence or absence of ZEB1 knockdown.
Supplementary Figure 2 from Redirecting Apoptosis to Aponecrosis Induces Selective Cytotoxicity to Pancreatic Cancer Cells through Increased ROS, Decline in ATP Levels, and VDAC
Authors: Dinnen Richard D. , Mao Yuehua , Qiu Wanglong , Cassai Nicholas , Slavkovich Vesna N. , Nichols Gwen , Su Gloria H. , Brandt-Rauf Paul , Fine Robert L.
Published: April 2023

PDF - 213KB, Supplementary Figure 2: A, Cell death determined by release of glucose 6-phosphate dehydrogenase. Results shown as a maximum release as determined by addition of cell lysis buffer, n=3. B, ATP analysis. PANC-1 cells +/- AAA or PAC, or MIA PaCa-2 +/- ATO (2 μM) +AA (100 μM), +/- DSF (0.25 μM), or +/- AAA in triplicate for 4h. Intracellular ATP levels were determined by luminometer at 560nm. Results expressed as % of untreated controls and represent mean luminosity +/- SD, n=3. C, Time course of LDH Release. Results expressed as maximal LDH release as determined by repeated freeze-thaw of cell cultures and represent mean absorbance. n=3.
Supplementary Figure 2C from Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma
Authors: Mirzoeva Olga K. , Collisson Eric A. , Schaefer Peter M. , Hann Byron , Hom Yun K. , Ko Andrew H. , Korn W. Michael
Published: April 2023

PDF - 1699K, Six cell lines were resistant to one or both single agents and their combination did not result in additional enhancement of the effect: the combined IC50 was less than 3 fold different than the lowest IC50 of a single drug, the response was classified as "no combinatorial effect".
Supplementary Figure 1 from Redirecting Apoptosis to Aponecrosis Induces Selective Cytotoxicity to Pancreatic Cancer Cells through Increased ROS, Decline in ATP Levels, and VDAC
Authors: Dinnen Richard D. , Mao Yuehua , Qiu Wanglong , Cassai Nicholas , Slavkovich Vesna N. , Nichols Gwen , Su Gloria H. , Brandt-Rauf Paul , Fine Robert L.
Published: April 2023

PDF - 964KB, Supplementary Figure 1: A, AsPC-1 or BxPC-3 cells were treated +/- ATO (2 μM), AA (100 μM) with increasing concentrations of DSF and % Trypan-blue (TPB)+ cells determined after 48h. B, Cell death in PANC-1, 27sk or MCF-10F cells +/- ATO (2 μM), AA (1 00 μM) +/- 0.25 μM DSF and % Trypan-blue (TPB)+ cells determined after 48h. For all experiments, the concentration of ATO, AA, and DSF were 2 μM, 100 μM and 0.25 μM, respectively, unless otherwise indicated. AAA=ATO+AA+DSF. For TPB analysis, at least 200 cells were scored/sample and performed in triplicate. All controls contained vehicle additions: DMSO <0.1% and NaOH <66 μM. Veh= vehicle control. C, Phase contrast microscopy of PANC-1 cells +/- ATO, AA and DSF (0.25 μM) for 48h. 100x Magnification.
Supplementary Figure 2B from Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma
Authors: Mirzoeva Olga K. , Collisson Eric A. , Schaefer Peter M. , Hann Byron , Hom Yun K. , Ko Andrew H. , Korn W. Michael
Published: April 2023

PDF - 2939K, 12 cell lines showed moderate synergy or potentiation: the combined IC50 was 3-6 fold lower than the lowest IC50 of the single agent.
Supplementary Figure 1 from Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma
Authors: Mirzoeva Olga K. , Collisson Eric A. , Schaefer Peter M. , Hann Byron , Hom Yun K. , Ko Andrew H. , Korn W. Michael
Published: April 2023

PDF - 67K, Chemical structures of Erlotinib, CI104 (PD184352), PD0325901.
Supplementary Figure 2 from The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models
Authors: Smyth Tomoko , Van Looy Thomas , Curry Jayne E. , Rodriguez-Lopez Ana M. , Wozniak Agnieszka , Zhu Meijun , Donsky Rachel , Morgan Jennifer G. , Mayeda Mark , Fletcher Jonathan A. , Schöffski Patrick , Lyons John , Thompson Neil T. , Wallis Nicola G.
Published: April 2023

PDF file, 289KB, Western immunoblots and their densitometric analyses showing the pharmacodynamic response of GIST430 xenograft to 22 days of AT13387, imatinib or combination treatment.
Supplementary Methods, Figures 1 - 3, Tables 1 - 3 from Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
Authors: Newbold Andrea , Matthews Geoffrey M. , Bots Michael , Cluse Leonie A. , Clarke Christopher J.P. , Banks Kellie-Marie , Cullinane Carleen , Bolden Jessica E. , Christiansen Ailsa J. , Dickins Ross A. , Miccolo Claudia , Chiocca Susanna , Kral Astrid M. , Ozerova Nicole D. , Miller Thomas A. , Methot Joey L. , Richon Victoria M. , Secrist J. Paul , Minucci Saverio , Johnstone Ricky W.
Published: April 2023

PDF file - 1496K, Supplementary Methods; Supplementary Figure 1: Production and characterisation of tumor cells dependent on Bcr-Abl for survival; Supplementary Figure 2: HDACi with different isoform specificities induce apoptosis of Bcr-Abl(p210) expressing cells; Supplementary Figure 3: Knockdown of HDAC6 does not induce the acetylation of histones or affect sensitivity to HDAC inhibitors; Supplementary Table 1: HDACi selectively inhibit a range of different HDACs; Supplementary Table 2: Pharmacokinetic analysis of vorinostat and MRLB-223; Supplementary Table 3: FDG uptake was measured at different times in the same animals using region of interest software (ROI) on the PET.
Supplementary Figure Legend from Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers
Authors: Cooper Simon J. , von Roemeling Christina A. , Kang Kylie H. , Marlow Laura A. , Grebe Stefan K. , Menefee Michael E. , Tun Han W. , Colon-Otero Gerardo , Perez Edith A. , Copland John A.
Published: April 2023

PDF file, 59K.
Supplementary Table 1 from The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells
Authors: Sehdev Vikas , Peng DunFa , Soutto Mohammed , Washington M. Kay , Revetta Frank , Ecsedy Jeffrey , Zaika Alexander , Rau Tilman T. , Schneider-Stock Regine , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

PDF file - 229K, Details of cell cycle analysis following MLN8237 and CDDPand CDDP.
Supplementary Figure 3 from Reexpression of Tumor Suppressor, sFRP1, Leads to Antitumor Synergy of Combined HDAC and Methyltransferase Inhibitors in Chemoresistant Cancers
Authors: Cooper Simon J. , von Roemeling Christina A. , Kang Kylie H. , Marlow Laura A. , Grebe Stefan K. , Menefee Michael E. , Tun Han W. , Colon-Otero Gerardo , Perez Edith A. , Copland John A.
Published: April 2023

PDF file, 130K, sFRP1 re-expression in cancer cells inhibits Wnt signaling.
Supplementary Figure Legends 1-3, Table Legend 1 from The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells
Authors: Sehdev Vikas , Peng DunFa , Soutto Mohammed , Washington M. Kay , Revetta Frank , Ecsedy Jeffrey , Zaika Alexander , Rau Tilman T. , Schneider-Stock Regine , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

PDF file - 45K
Supplementary Figure 2 from The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells
Authors: Sehdev Vikas , Peng DunFa , Soutto Mohammed , Washington M. Kay , Revetta Frank , Ecsedy Jeffrey , Zaika Alexander , Rau Tilman T. , Schneider-Stock Regine , Belkhiri Abbes , El-Rifai Wael
Published: April 2023

PDF file - 155K, Effects of MLN8237 and CDDP on cell cycle progression.
Supplementary Figure Legend from Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy
Authors: Iglesias David A. , Yates Melinda S. , van der Hoeven Dharini , Rodkey Travis L. , Zhang Qian , Co Ngai Na , Burzawa Jennifer , Chigurupati Sravanthi , Celestino Joseph , Bowser Jessica , Broaddus Russell , Hancock John F. , Schmandt Rosemarie , Lu Karen H.
Published: April 2023

PDF file - 41K
Supplementary Figure 2 from Another Surprise from Metformin: Novel Mechanism of Action via K-Ras Influences Endometrial Cancer Response to Therapy
Authors: Iglesias David A. , Yates Melinda S. , van der Hoeven Dharini , Rodkey Travis L. , Zhang Qian , Co Ngai Na , Burzawa Jennifer , Chigurupati Sravanthi , Celestino Joseph , Bowser Jessica , Broaddus Russell , Hancock John F. , Schmandt Rosemarie , Lu Karen H.
Published: April 2023

PDF file - 58K, Immunohistochemical analysis of pS6rp expression in endometrial cancer xenograft tumors.
Supplementary Materials and Methods from PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
Authors: Saha Manujendra N. , Jiang Hua , Yang Yijun , Reece Donna , Chang Hong
Published: April 2023

PDF - 68KB, Protocol for Microarray analysis and Quantitative RT-PCR (qPCR) MM.1S, U266, and 8266R5 cells were treated with 20, 40, and 40 microM PRIMA-1Met, respectively for 8 hrs and total RNA was isolated. Gene expression was analyzed with Illumina RNA analysis Beadchips (Illumina Inc. San Diego, CA) representing ∼48,000 human genes (Human HT12) as described by us earlier. (28.29) Array data analysis was carried out with Bead Studio software as reported previously. (28,29) Genes showing at least a 2.0-fold difference in expression levels between control and PRIMA-1Met-treated cells were considered to be modulated by PRIMA-1Met. To quantify and validate the expression of p53 target genes of interest at their mRNA level, qRT-PCR assays using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a reference gene were performed as described previously. (28,29)
Supplementary Table 4 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
Authors: Siemeister Gerhard , Lücking Ulrich , Wengner Antje M. , Lienau Philip , Steinke Wolfram , Schatz Christoph , Mumberg Dominik , Ziegelbauer Karl
Published: April 2023

PDF file, 63K, Cell line panels.
Supplementary Table 3 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
Authors: Siemeister Gerhard , Lücking Ulrich , Wengner Antje M. , Lienau Philip , Steinke Wolfram , Schatz Christoph , Mumberg Dominik , Ziegelbauer Karl
Published: April 2023

PDF file, 64K, Antiproliferation data.
Supplementary Figure 2 from PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
Authors: Saha Manujendra N. , Jiang Hua , Yang Yijun , Reece Donna , Chang Hong
Published: April 2023

PDF - 62KB, Supplementary Figure 2. PRIMA-1Met induces transcriptional regulation of a set of apoptosis target genes. (A) Microarray analysis of gene expression in MM.1S, U266, and 8266R5 cells after 8 hrs treatment with PRIMA-1Met. The heat map of genes differentially expressed in 3 MM cell lines in duplicates. Vertical rows indicate separate arrays, and horizontal rows indicate genes. Values are normalized to untreated control. Green indicates low expression; red indicates high expression. (B) mRNA levels of some of the selected genes modulated by PRIMA-1Met were detected by qRT-PCR in 3 MM cell lines treated similarly with PRIMA-1Met. Values were normalized to those obtained for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and expressed as log2-fold induction over DMSO-treated cells (mean plus or minus SD).
Supplementary Table 2 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
Authors: Siemeister Gerhard , Lücking Ulrich , Wengner Antje M. , Lienau Philip , Steinke Wolfram , Schatz Christoph , Mumberg Dominik , Ziegelbauer Karl
Published: April 2023

PDF file, 7K, Kinase inhibition data.
Supplementary Figure 1 from PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
Authors: Saha Manujendra N. , Jiang Hua , Yang Yijun , Reece Donna , Chang Hong
Published: April 2023

PDF - 53KB, Supplementary Figure 1. PRIMA-1Met restores wild type conformation of p53. U266 and MM.1S cells were treated with 50 micromol/L PRIMA-1Met for 8 hrs and cellular lysates were harvested. Proteins were immunoprecipitated with conformation specific pAb1620 antibody or rabbit IgG isotype control, and were detected with pAb1620 and pAb240 antibody. Lysates were run in parallel and probed with α-tubulin for loading control; C: control and P: PRIMA-1Met.
Supplementary Table 1 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
Authors: Siemeister Gerhard , Lücking Ulrich , Wengner Antje M. , Lienau Philip , Steinke Wolfram , Schatz Christoph , Mumberg Dominik , Ziegelbauer Karl
Published: April 2023

PDF file, 63K, Cell line sources and authentication.
Supplementary Table 1 from Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Authors: Gozgit Joseph M. , Wong Matthew J. , Moran Lauren , Wardwell Scott , Mohemmad Qurish K. , Narasimhan Narayana I. , Shakespeare William C. , Wang Frank , Clackson Tim , Rivera Victor M.
Published: April 2023

PDF file - 73K
Supplementary Methods, Figure Legends 1-6 from Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Authors: Gozgit Joseph M. , Wong Matthew J. , Moran Lauren , Wardwell Scott , Mohemmad Qurish K. , Narasimhan Narayana I. , Shakespeare William C. , Wang Frank , Clackson Tim , Rivera Victor M.
Published: April 2023

PDF file - 89K
Supplementary Figures 1-6 from Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Authors: Gozgit Joseph M. , Wong Matthew J. , Moran Lauren , Wardwell Scott , Mohemmad Qurish K. , Narasimhan Narayana I. , Shakespeare William C. , Wang Frank , Clackson Tim , Rivera Victor M.
Published: April 2023

PDF file - 457K
Supplementary Table 1 from HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporter–Mediated Chemoresistance in Small Cell Lung Cancer
Authors: Minami Toshiyuki , Kijima Takashi , Otani Yasushi , Kohmo Satoshi , Takahashi Ryo , Nagatomo Izumi , Hirata Haruhiko , Suzuki Mayumi , Inoue Koji , Takeda Yoshito , Kida Hiroshi , Tachibana Isao , Kumanogoh Atsushi
Published: April 2023

PDF file - 62K, Reversal effect of lapatinib on multidrug resistance. Cells (5�103 cells/well) were plated onto 96-well tissue culture-treated plates and treated with serially diluted cytotoxic drugs with or without lapatinib in serum containing medium for 72 h. The relative number of viable cells was quantified using CCK-8. IC50 concentration for each drug was calculated and presented as the mean � SD. Each experiment was done in triplicate and repeated at least thrice.
Supplementary Table 3 from Uracil–DNA Glycosylase Expression Determines Human Lung Cancer Cell Sensitivity to Pemetrexed
Authors: Weeks Lachelle D. , Fu Pingfu , Gerson Stanton L.
Published: April 2023

PDF file - 88K, Multivariable regression statistics for 'UNG+Gene' pairs.
Supplementary Table 2 from Uracil–DNA Glycosylase Expression Determines Human Lung Cancer Cell Sensitivity to Pemetrexed
Authors: Weeks Lachelle D. , Fu Pingfu , Gerson Stanton L.
Published: April 2023

PDF file - 80K, ummary of correlation of linear regression calculations for UNG, SMUG1, TDG, MBD4, POLβ, TOPOIIα, and TYMS.
Supplementary Figure 3 from HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporter–Mediated Chemoresistance in Small Cell Lung Cancer
Authors: Minami Toshiyuki , Kijima Takashi , Otani Yasushi , Kohmo Satoshi , Takahashi Ryo , Nagatomo Izumi , Hirata Haruhiko , Suzuki Mayumi , Inoue Koji , Takeda Yoshito , Kida Hiroshi , Tachibana Isao , Kumanogoh Atsushi
Published: April 2023

PDF file - 66K, HER2 is successfully knocked down using siRNA technique. Successful knock down of HER2 using siRNA technique in SBC-3/ETP cells and SBC-3/SN-38 cells was confirmed by FACS and immunoblotting. HER2-targeting siRNA markedly suppressed HER2 expression without affecting ABCB1 and ABCG2 expression.
Supplementary Figure 2 from HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporter–Mediated Chemoresistance in Small Cell Lung Cancer
Authors: Minami Toshiyuki , Kijima Takashi , Otani Yasushi , Kohmo Satoshi , Takahashi Ryo , Nagatomo Izumi , Hirata Haruhiko , Suzuki Mayumi , Inoue Koji , Takeda Yoshito , Kida Hiroshi , Tachibana Isao , Kumanogoh Atsushi
Published: April 2023

PDF file - 130K, EGFR is expressed in SBC-3/ETP cells but not in SBC-3/SN-38 cells. Immunoblotting analysis revealed that expression of EGFR, another target molecule of lapatinib, is upregulated in SBC-3/ETP cells but not in SBC-3/SN-38 cells.
Supplementary Methods and Figure Legend from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis
Authors: Ying Meidan , Zhou Xinglu , Zhong Like , Lin Nengming , Jing Hui , Luo Peihua , Yang Xiaochun , Song Hua , Yang Bo , He Qiaojun
Published: April 2023

PDF file - 147K
Supplementary Table 1 from The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants
Authors: Medová Michaela , Pochon Benoît , Streit Bruno , Blank-Liss Wieslawa , Francica Paola , Stroka Deborah , Keogh Adrian , Aebersold Daniel M. , Blaukat Andree , Bladt Friedhelm , Zimmer Yitzhak
Published: April 2023

PDF - 35KB, Supplementary table 1 - Fold increase in dead cells upon EMD1214063 treatment as compared to untreated cells in eight studied MET mutated variants.
Supplementary Figure 2 from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis
Authors: Ying Meidan , Zhou Xinglu , Zhong Like , Lin Nengming , Jing Hui , Luo Peihua , Yang Xiaochun , Song Hua , Yang Bo , He Qiaojun
Published: April 2023

PDF file - 186K, The effect of bortezomib (BTZ) and ATRA on PML-RARα expression in NB4 cells.
Supplementary Figure and Table Legends from The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants
Authors: Medová Michaela , Pochon Benoît , Streit Bruno , Blank-Liss Wieslawa , Francica Paola , Stroka Deborah , Keogh Adrian , Aebersold Daniel M. , Blaukat Andree , Bladt Friedhelm , Zimmer Yitzhak
Published: April 2023

PDF - 36KB, Legends for Supplementary Figure 1 and Supplementary Table 1.
Supplementary Figure 1 from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis
Authors: Ying Meidan , Zhou Xinglu , Zhong Like , Lin Nengming , Jing Hui , Luo Peihua , Yang Xiaochun , Song Hua , Yang Bo , He Qiaojun
Published: April 2023

PDF file - 1900K, Bortezomib (BTZ) synergized with ATRA to inhibit AML cell proliferation.
Supplementary Methods from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Authors: Sutherland Mark , Gill Jason H. , Loadman Paul M. , Laye Jonathan P. , Sheldrake Helen M. , Illingworth Nicola A. , Alandas Mohammed N. , Cooper Patricia A. , Searcey Mark , Pors Klaus , Shnyder Steve D. , Patterson Laurence H.
Published: April 2023

PDF file - 109K, Methodology for analysis of CYP1 gene and protein expression,Detection of DNA-damage induced gamma-H2AX protein expression, and analysis of ICT2700 metabolism in mouse and human liver ex vivo
Supplementary Figure 5 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
Authors: Li Huifang , Hassona Mohamed D.H. , Lack Nathan A. , Axerio-Cilies Peter , Leblanc Eric , Tavassoli Peyman , Kanaan Natalia , Frewin Kate , Singh Kriti , Adomat Hans , Böhm Konrad J. , Prinz Helge , Guns Emma Tomlinson , Rennie Paul S. , Cherkasov Artem
Published: April 2023

PDF file, 3480K, The binding pose of DHT (A) and VPC-3022 with AR by molecular docking (B) and binding pose of VPC-3022 with AR after 10 ns molecular dynamics (C); RMSD values of the protein backbone, protein-ligand, ligand in the 10 ns molecular dynamics for AR-DHT (D) and AR-VPC-3022 (E).
Supplementary Figure 2 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Authors: Sutherland Mark , Gill Jason H. , Loadman Paul M. , Laye Jonathan P. , Sheldrake Helen M. , Illingworth Nicola A. , Alandas Mohammed N. , Cooper Patricia A. , Searcey Mark , Pors Klaus , Shnyder Steve D. , Patterson Laurence H.
Published: April 2023

PDF file - 107K, In vivo metabolic profile of tumour and liver after administration of ICT2700 to CYP1A1 tumor-bearing mice
Supplementary Figure 3 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
Authors: Li Huifang , Hassona Mohamed D.H. , Lack Nathan A. , Axerio-Cilies Peter , Leblanc Eric , Tavassoli Peyman , Kanaan Natalia , Frewin Kate , Singh Kriti , Adomat Hans , Böhm Konrad J. , Prinz Helge , Guns Emma Tomlinson , Rennie Paul S. , Cherkasov Artem
Published: April 2023

PDF file, 162K, AR mRNA levels are unaffected upon treatment with VPC-3022 and VPC-3033. Total RNA was extracted after treatment of LNCaP and MDV3100-resistant cells with VPC-3022 and VPC-3033 for 24 hours at the indicated concentrations in the presence of 0.1 nM R1881. Quantitative RT-PCR analysis of AR expression was performed and normalized to 18S rRNA levels. Error bars indicate standard deviation.
Supplementary Figure 1 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Authors: Sutherland Mark , Gill Jason H. , Loadman Paul M. , Laye Jonathan P. , Sheldrake Helen M. , Illingworth Nicola A. , Alandas Mohammed N. , Cooper Patricia A. , Searcey Mark , Pors Klaus , Shnyder Steve D. , Patterson Laurence H.
Published: April 2023

PDF file - 120K, Representative CYP1A1 activity of the EJ138 bladder cell line and EJ138-1A1 bladder cell line, determined by measurement of Ethoxyresorufin O-de-ethylation
Supplementary Figure Legends 1-5 from Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer
Authors: Kumano Masafumi , Furukawa Junya , Shiota Masaki , Zardan Anousheh , Zhang Fan , Beraldi Eliana , Wiedmann Romina M. , Fazli Ladan , Zoubeidi Amina , Gleave Martin E.
Published: April 2023

PDF file - 88K
Supplementary Figure 1 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
Authors: Li Huifang , Hassona Mohamed D.H. , Lack Nathan A. , Axerio-Cilies Peter , Leblanc Eric , Tavassoli Peyman , Kanaan Natalia , Frewin Kate , Singh Kriti , Adomat Hans , Böhm Konrad J. , Prinz Helge , Guns Emma Tomlinson , Rennie Paul S. , Cherkasov Artem
Published: April 2023

PDF file, 1192K, Chemical structures of current antiandrogens with common motifs highlighted.
Supplementary Figure 5 from Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer
Authors: Kumano Masafumi , Furukawa Junya , Shiota Masaki , Zardan Anousheh , Zhang Fan , Beraldi Eliana , Wiedmann Romina M. , Fazli Ladan , Zoubeidi Amina , Gleave Martin E.
Published: April 2023

PDF file - 164K, Combination of Hsp27 inhibition with autophagy inhibitors 3-Methyladenine (3-MA) or Chloroquine (CQ) increases cytotoxicity in PC3 cells
Supplementary Table 1 from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
Authors: Damiano Jason S. , Rendahl Katherine G. , Karim Christopher , Embry Millicent G. , Ghoddusi Majid , Holash Jocelyn , Fanidi Abdallah , Abrams Tinya J. , Abraham Judith A.
Published: April 2023

PDF file - 55KB, Pharmacokinetic properties of LFA102 in rodents
Supplementary Figure 3 from Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer
Authors: Kumano Masafumi , Furukawa Junya , Shiota Masaki , Zardan Anousheh , Zhang Fan , Beraldi Eliana , Wiedmann Romina M. , Fazli Ladan , Zoubeidi Amina , Gleave Martin E.
Published: April 2023

PDF file - 110K, Hsp27 knockdown induces ER stress in LNCaP cells
Supplementary Methods from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
Authors: Damiano Jason S. , Rendahl Katherine G. , Karim Christopher , Embry Millicent G. , Ghoddusi Majid , Holash Jocelyn , Fanidi Abdallah , Abrams Tinya J. , Abraham Judith A.
Published: April 2023

PDF file - 120KB
Supplementary Figure 2 from Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer
Authors: Kumano Masafumi , Furukawa Junya , Shiota Masaki , Zardan Anousheh , Zhang Fan , Beraldi Eliana , Wiedmann Romina M. , Fazli Ladan , Zoubeidi Amina , Gleave Martin E.
Published: April 2023

PDF file - 96K, Hsp27 overexpression prevents cell apoptosis induced by MG132 or Hsp90 inhibitor (17-AAG) in LNCaP cells
Supplementary Figure 1 from Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer
Authors: Kumano Masafumi , Furukawa Junya , Shiota Masaki , Zardan Anousheh , Zhang Fan , Beraldi Eliana , Wiedmann Romina M. , Fazli Ladan , Zoubeidi Amina , Gleave Martin E.
Published: April 2023

PDF file - 58K, PC-3 cells stably overexpressing Hsp27 show similar cell growth and apoptotic rates compared to parental or empty vector under basal, unstressed conditions
Supplementary Figure S4 from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
Authors: Damiano Jason S. , Rendahl Katherine G. , Karim Christopher , Embry Millicent G. , Ghoddusi Majid , Holash Jocelyn , Fanidi Abdallah , Abrams Tinya J. , Abraham Judith A.
Published: April 2023

PDF file - 59KB, Correlation between serum LFA102 and serum PRL over time in rats
Supplementary Methods, Figure Legends 1-3 from CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
Authors: Siddiqui-Jain Adam , Bliesath Joshua , Macalino Diwata , Omori Mayuko , Huser Nanni , Streiner Nicole , Ho Caroline B. , Anderes Kenna , Proffitt Chris , O'Brien Sean E. , Lim John K. C. , Von Hoff Daniel D. , Ryckman David M. , Rice William G. , Drygin Denis
Published: April 2023

PDF file - 63K
Supplementary Figure S2 from Neutralization of Prolactin Receptor Function by Monoclonal Antibody LFA102, a Novel Potential Therapeutic for the Treatment of Breast Cancer
Authors: Damiano Jason S. , Rendahl Katherine G. , Karim Christopher , Embry Millicent G. , Ghoddusi Majid , Holash Jocelyn , Fanidi Abdallah , Abrams Tinya J. , Abraham Judith A.
Published: April 2023

PDF file - 77KB, Pharmacodynamic effects of LFA102 in the rat mammary gland
Supplementary Figure 3 from CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
Authors: Siddiqui-Jain Adam , Bliesath Joshua , Macalino Diwata , Omori Mayuko , Huser Nanni , Streiner Nicole , Ho Caroline B. , Anderes Kenna , Proffitt Chris , O'Brien Sean E. , Lim John K. C. , Von Hoff Daniel D. , Ryckman David M. , Rice William G. , Drygin Denis
Published: April 2023

PDF file - 1.0MB, The global role of CK2 in DNA repair and cancer therapies that potentially rely on CK2 mediated repair mechanisms.
Supplemental Figure 8 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
Authors: Blackwood Elizabeth , Epler Jennifer , Yen Ivana , Flagella Michael , O'Brien Tom , Evangelista Marie , Schmidt Stephen , Xiao Yang , Choi Jonathan , Kowanetz Kaska , Ramiscal Judi , Wong Kenton , Jakubiak Diana , Yee Sharon , Cain Gary , Gazzard Lewis , Williams Karen , Halladay Jason , Jackson Peter K. , Malek Shiva
Published: April 2023

Pharmacokinetics of GNE-900 in female CD-1 mice or male Sprague-Dawley rats.
Supplemental Figure 6 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
Authors: Blackwood Elizabeth , Epler Jennifer , Yen Ivana , Flagella Michael , O'Brien Tom , Evangelista Marie , Schmidt Stephen , Xiao Yang , Choi Jonathan , Kowanetz Kaska , Ramiscal Judi , Wong Kenton , Jakubiak Diana , Yee Sharon , Cain Gary , Gazzard Lewis , Williams Karen , Halladay Jason , Jackson Peter K. , Malek Shiva
Published: April 2023

GNE-900 potentiates the cytotoxicity of gemcitabine in HCT-116 isogenic variants, irrespective of NHEJ competence.
Supplementary Figure 2 from IGF-1R/MDM2 Relationship Confers Enhanced Sensitivity to RITA in Ewing Sarcoma Cells
Authors: Di Conza Giusy , Buttarelli Marianna , Monti Olimpia , Pellegrino Marsha , Mancini Francesca , Pontecorvi Alfredo , Scotlandi Katia , Moretti Fabiola
Published: April 2023

PDF file, 93KB, IGF-1R and MDM2 protein levels upon RITA treatment in WE-68 and IOR-BRZ71 cells.
Supplemental Figure 4 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
Authors: Blackwood Elizabeth , Epler Jennifer , Yen Ivana , Flagella Michael , O'Brien Tom , Evangelista Marie , Schmidt Stephen , Xiao Yang , Choi Jonathan , Kowanetz Kaska , Ramiscal Judi , Wong Kenton , Jakubiak Diana , Yee Sharon , Cain Gary , Gazzard Lewis , Williams Karen , Halladay Jason , Jackson Peter K. , Malek Shiva
Published: April 2023

GNE-900 can potentiate the cytotoxicity of gemcitabine, SN-38 and pemetrexed.
Supplementary Figure 1 from IGF-1R/MDM2 Relationship Confers Enhanced Sensitivity to RITA in Ewing Sarcoma Cells
Authors: Di Conza Giusy , Buttarelli Marianna , Monti Olimpia , Pellegrino Marsha , Mancini Francesca , Pontecorvi Alfredo , Scotlandi Katia , Moretti Fabiola
Published: April 2023

PDF file, 53KB, FACS analysis of IOR-BRZ71, WE-68 and 6647 cells upon RITA treatment.
Supplemental Figure 3 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
Authors: Blackwood Elizabeth , Epler Jennifer , Yen Ivana , Flagella Michael , O'Brien Tom , Evangelista Marie , Schmidt Stephen , Xiao Yang , Choi Jonathan , Kowanetz Kaska , Ramiscal Judi , Wong Kenton , Jakubiak Diana , Yee Sharon , Cain Gary , Gazzard Lewis , Williams Karen , Halladay Jason , Jackson Peter K. , Malek Shiva
Published: April 2023

Representative data from a cell-based checkpoint abrogation assay.
Supplemental Figure 2 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
Authors: Blackwood Elizabeth , Epler Jennifer , Yen Ivana , Flagella Michael , O'Brien Tom , Evangelista Marie , Schmidt Stephen , Xiao Yang , Choi Jonathan , Kowanetz Kaska , Ramiscal Judi , Wong Kenton , Jakubiak Diana , Yee Sharon , Cain Gary , Gazzard Lewis , Williams Karen , Halladay Jason , Jackson Peter K. , Malek Shiva
Published: April 2023

Representative data from enzyme assays evaluating the relative potency of GNE-900 against ChK1 or ChK2.
Supplementary Table 1 from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
Authors: Song Bing , Liu X. Shawn , Rice Steven J. , Kuang Shihuan , Elzey Bennett D. , Konieczny Stephen F. , Ratliff Timothy L. , Hazbun Tony , Chiorean Elena G. , Liu Xiaoqi
Published: April 2023

PDF file - 17K, The IC50 values of Gemcitabine in Pancreatic cell lines
Supplemental Figure 1 from Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900
Authors: Blackwood Elizabeth , Epler Jennifer , Yen Ivana , Flagella Michael , O'Brien Tom , Evangelista Marie , Schmidt Stephen , Xiao Yang , Choi Jonathan , Kowanetz Kaska , Ramiscal Judi , Wong Kenton , Jakubiak Diana , Yee Sharon , Cain Gary , Gazzard Lewis , Williams Karen , Halladay Jason , Jackson Peter K. , Malek Shiva
Published: April 2023

Kinase selectivity profile evaluated at 100 nM GNE-900
Supplementary Methods, Table 1, Figures 1-3 from Hyperactivation of 4E-Binding Protein 1 as a Mediator of Biguanide-Induced Cytotoxicity during Glucose Deprivation
Authors: Matsuo Junichi , Tsukumo Yoshinori , Saito Sakae , Tsukahara Satomi , Sakurai Junko , Sato Shigeo , Kondo Hiromichi , Ushijima Masaru , Matsuura Masaaki , Watanabe Toshiki , Tomida Akihiro
Published: April 2023

PDF file - 292K, hyperactivation of 4E-BP1 in UPR inhibition
Supplementary Table 1 from Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells
Authors: Ronca Roberto , Di Salle Emanuela , Giacomini Arianna , Leali Daria , Alessi Patrizia , Coltrini Daniela , Ravelli Cosetta , Matarazzo Sara , Ribatti Domenico , Vermi William , Presta Marco
Published: April 2023

PDF - 33KB, List of oligonucleotide primers utilized for PCR experiments.
Supplementary Figure 1 from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
Authors: Song Bing , Liu X. Shawn , Rice Steven J. , Kuang Shihuan , Elzey Bennett D. , Konieczny Stephen F. , Ratliff Timothy L. , Hazbun Tony , Chiorean Elena G. , Liu Xiaoqi
Published: April 2023

PDF file - 44K, Inhibition of Plk1 sensitizes cells to gemcitabine
Supplementary Figure 4 from Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells
Authors: Ronca Roberto , Di Salle Emanuela , Giacomini Arianna , Leali Daria , Alessi Patrizia , Coltrini Daniela , Ravelli Cosetta , Matarazzo Sara , Ribatti Domenico , Vermi William , Presta Marco
Published: April 2023

PDF - 117KB, PTX3 expression in human melanoma.
Supplementary Materials and Methods from Designing and Developing S100P Inhibitor 5-Methyl Cromolyn for Pancreatic Cancer Therapy
Authors: Arumugam Thiruvengadam , Ramachandran Vijaya , Sun Duoli , Peng Zhenghong , Pal Ashutosh , Maxwell David S. , Bornmann William G. , Logsdon Craig D.
Published: April 2023

PDF file - 124 KB, Synthesis of Cromolyn Analogs:Lead compound C5OH synthesis is presented in material and method sections. Other analogs synthesis procedure is provided as supplementary material.
Supplementary Figure 3 from Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells
Authors: Ronca Roberto , Di Salle Emanuela , Giacomini Arianna , Leali Daria , Alessi Patrizia , Coltrini Daniela , Ravelli Cosetta , Matarazzo Sara , Ribatti Domenico , Vermi William , Presta Marco
Published: April 2023

PDF - 65KB, Matrigel implant assay.
Supplementary Figure 3 from Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-Dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer
Authors: Liu Xinyi , Jutooru Indira , Lei Ping , Kim KyoungHyun , Lee Syng-ook , Brents Lisa K. , Prather Paul L. , Safe Stephen
Published: April 2023

PDF file, 104KB, BA-mediated downregulation of Sp1, Sp3 and Sp4 partially blocked by CB receptor antagonists.
Supplementary Figure 1 from Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells
Authors: Ronca Roberto , Di Salle Emanuela , Giacomini Arianna , Leali Daria , Alessi Patrizia , Coltrini Daniela , Ravelli Cosetta , Matarazzo Sara , Ribatti Domenico , Vermi William , Presta Marco
Published: April 2023

PDF - 37KB, hPTX3 overexpression in B16-F10 cells.
Supplementary Figure 2 from Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-Dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer
Authors: Liu Xinyi , Jutooru Indira , Lei Ping , Kim KyoungHyun , Lee Syng-ook , Brents Lisa K. , Prather Paul L. , Safe Stephen
Published: April 2023

PDF file, 58KB, Knockdown of YY1 decreases protein levels of ErbB2 in BT474 and MDA-MB-453 cells.
Supplementary Figure Legend from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Authors: Ortenberg Rona , Sapir Yair , Raz Lee , Hershkovitz Liat , Ben Arav Ayelet , Sapoznik Sivan , Barshack Iris , Avivi Camila , Berkun Yackov , Besser Michal J. , Ben-Moshe Tehila , Schachter Jacob , Markel Gal
Published: April 2023

PDF file, 43KB.
Supplementary Figure 4 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Authors: Ortenberg Rona , Sapir Yair , Raz Lee , Hershkovitz Liat , Ben Arav Ayelet , Sapoznik Sivan , Barshack Iris , Avivi Camila , Berkun Yackov , Besser Michal J. , Ben-Moshe Tehila , Schachter Jacob , Markel Gal
Published: April 2023

PDF file, 54KB, Stability of CEACAM1 expression on injected T cells and its persistence in in vivo model.
Supplementary Figure 3 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Authors: Ortenberg Rona , Sapir Yair , Raz Lee , Hershkovitz Liat , Ben Arav Ayelet , Sapoznik Sivan , Barshack Iris , Avivi Camila , Berkun Yackov , Besser Michal J. , Ben-Moshe Tehila , Schachter Jacob , Markel Gal
Published: April 2023

PDF file, 42KB, MRG1 synergizes with adoptively transferred human TIL in xenograft model.
Supplementary Methods from Small-Molecule Inhibitors of Acetyltransferase p300 Identified by High-Throughput Screening Are Potent Anticancer Agents
Authors: Yang Heng , Pinello Christie E. , Luo Jian , Li Dawei , Wang Yunfei , Zhao Lisa Y. , Jahn Stephan C. , Saldanha Sanjay Adrian , Planck Jamie , Geary Kyla R. , Ma Haiching , Law Brian K. , Roush William R. , Hodder Peter , Liao Daiqing
Published: April 2023

PDF file - 36K
Supplementary Table 2 from Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells
Authors: Matsuda Yoko , Hagio Masahito , Seya Tomoko , Ishiwata Toshiyuki
Published: April 2023

PDF file, 54K, Functions of altered genes in FGFR2IIIc monoclonal antibody-treated colorectal cancer cells.
Supplementary Table 1 from Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells
Authors: Matsuda Yoko , Hagio Masahito , Seya Tomoko , Ishiwata Toshiyuki
Published: April 2023

PDF file, 82K, Genes that were increased or decreased more than two-fold in anti-FGFR2IIIc monoclonal antibody-treated cells.
Supplementary Materials and Methods from Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors
Authors: Ghadimi Markus P. , Lopez Gonzalo , Torres Keila E. , Belousov Roman , Young Eric D. , Liu Jeffery , Brewer Kari J. , Hoffman Aviad , Lusby Kristelle , Lazar Alexander J. , Pollock Raphael E. , Lev Dina
Published: April 2023

PDF file - 98K
Supplementary Figure Legend from Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells
Authors: Matsuda Yoko , Hagio Masahito , Seya Tomoko , Ishiwata Toshiyuki
Published: April 2023

PDF file, 60K.
Supplementary Table 1 from Sorafenib-Induced Hepatocellular Carcinoma Cell Death Depends on Reactive Oxygen Species Production In Vitro and In Vivo
Authors: Coriat Romain , Nicco Carole , Chéreau Christiane , Mir Olivier , Alexandre Jérôme , Ropert Stanislas , Weill Bernard , Chaussade Stanislas , Goldwasser François , Batteux Frédéric
Published: April 2023

PDF file, 82K, Relationship between the dosage of sorafenib, serum AOPP levels and drug toxicity.
Supplementary Table 2 from Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
Authors: Ying Weiwen , Du Zhenjian , Sun Lijun , Foley Kevin P. , Proia David A. , Blackman Ronald K. , Zhou Dan , Inoue Takayo , Tatsuta Noriaki , Sang Jim , Ye Shuxia , Acquaviva Jamie , Ogawa Luisa Shin , Wada Yumiko , Barsoum James , Koya Keizo
Published: April 2023

PDF fiel - 59K
Supplementary Table 1 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
Authors: Nakagawa Takayuki , Takeuchi Shinji , Yamada Tadaaki , Nanjo Shigeki , Ishikawa Daisuke , Sano Takako , Kita Kenji , Nakamura Takahiro , Matsumoto Kunio , Suda Kenichi , Mitsudomi Tetsuya , Sekido Yoshitaka , Uenaka Toshimitsu , Yano Seiji
Published: April 2023

PDF file, 40K, Supplementary Table S1 IC50 values of each compound in MTT assay.
Supplementary Table 1 from Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
Authors: Ying Weiwen , Du Zhenjian , Sun Lijun , Foley Kevin P. , Proia David A. , Blackman Ronald K. , Zhou Dan , Inoue Takayo , Tatsuta Noriaki , Sang Jim , Ye Shuxia , Acquaviva Jamie , Ogawa Luisa Shin , Wada Yumiko , Barsoum James , Koya Keizo
Published: April 2023

PDF file - 71K
Supplementary Figure Legend from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
Authors: Nakagawa Takayuki , Takeuchi Shinji , Yamada Tadaaki , Nanjo Shigeki , Ishikawa Daisuke , Sano Takako , Kita Kenji , Nakamura Takahiro , Matsumoto Kunio , Suda Kenichi , Mitsudomi Tetsuya , Sekido Yoshitaka , Uenaka Toshimitsu , Yano Seiji
Published: April 2023

PDF file, 73K.
Supplementary Methods, Figures 1-2 from Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
Authors: Ying Weiwen , Du Zhenjian , Sun Lijun , Foley Kevin P. , Proia David A. , Blackman Ronald K. , Zhou Dan , Inoue Takayo , Tatsuta Noriaki , Sang Jim , Ye Shuxia , Acquaviva Jamie , Ogawa Luisa Shin , Wada Yumiko , Barsoum James , Koya Keizo
Published: April 2023

PDF file - 126K
Supplementary Figure 5 from Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells Producing IL15 Eradicate Established Pancreatic Tumor in Syngeneic Mice
Authors: Jing Wei , Chen Ying , Lu Lei , Hu Xiangui , Shao Chenghao , Zhang Yijie , Zhou Xuyu , Zhou Yingqi , Wu Lang , Liu Rui , Fan Kexing , Jin Gang
Published: April 2023

PDF - 115K, (A) Intratumor infiltration of CD4+FoxP3+ regulatory T cells were determined by flow cytometry at 10 days after MSC-IL-15 injection. (B) mRNA levels of Foxp3 in tumor tissue were detected by qRT-PCR. (C) MSC-GFP with tumor cells was co-injected, and 7 days later, MSC-IL-15 was administrated. Tumor growth was recorded over time. *, P<0.05; **, P<0.01.
Supplementary Table 2 from MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
Authors: Asundi Jyoti , Lacap Jennifer A. , Clark Suzanna , Nannini Michelle , Roth Leslie , Polakis Paul
Published: April 2023

PDF file - 56KB, efficacy p values.
Supplementary Figure 3 from Human Umbilical Cord Blood–Derived Mesenchymal Stem Cells Producing IL15 Eradicate Established Pancreatic Tumor in Syngeneic Mice
Authors: Jing Wei , Chen Ying , Lu Lei , Hu Xiangui , Shao Chenghao , Zhang Yijie , Zhou Xuyu , Zhou Yingqi , Wu Lang , Liu Rui , Fan Kexing , Jin Gang
Published: April 2023

PDF - 113K, MSC-IL-15 suppresses Pan02 tumor growth via a cell dose-dependent manner. 1x106 Pan02 tumor cells were injected into C57BL/6 mice substancuously. After 7 days, various cell doses of MSC-IL-15 were administrated by i.v. injection. Tumor growth was recorded over time. **,P<0.01.
Supplementary Table 1 from MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
Authors: Asundi Jyoti , Lacap Jennifer A. , Clark Suzanna , Nannini Michelle , Roth Leslie , Polakis Paul
Published: April 2023

PDF file - 436KB, efficacy stats.